ZLY06 is a dual agonisT of peroxisome proliferaTor-acTivaTed recepTors (PPAR) δ and γ wiTh oral acTiviTy (PPAR δ: EC50=341 nM; PPARγ: EC50=237 nM). IT mediaTes The upregulaTion of CD36 and induces hepaTic lipid accumulaTion by inhibiTing The phosphorylaTion of AKT1. Moreover, ZLY06 significanTly improves glucose and lipid meTabolism wiThouT increasing body weighT, primarily by enhancing The β-oxidaTion of faTTy acids and reducing hepaTic lipid synThesis, Thereby alleviaTing faTTy liver disease.

PPARγ:237 nM, PPARδ:341 nM